A Randomized, Investigator and Subject Blinded, Sponsor Unblinded Placebo-Controlled Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects

Trial Profile

A Randomized, Investigator and Subject Blinded, Sponsor Unblinded Placebo-Controlled Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs TAK 831 (Primary)
  • Indications Ataxia; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 13 Apr 2018 Planned End Date changed from 1 Jun 2018 to 30 Jul 2018.
    • 13 Apr 2018 Planned primary completion date changed from 1 May 2018 to 30 Jul 2018.
    • 16 Feb 2018 Planned End Date changed from 20 Feb 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top